Quadrucept Bio Revenue

Biotechnology Research • • 1-10 Employees

Quadrucept Bio revenue & valuation

Annual revenue	$171,110
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$547,552
Total funding	No funding

Key Contact at Quadrucept Bio

Steve Arkinstall

Co-Founder and Chief Scientific Officer

Company overview

Headquarters	XX
Website	quadruceptbio.com
NAICS	541714
Keywords	Half-Life Extension, Antibody Based Drugs, Avidity Driven Super Antagonists, High Potency Receptor-Fc Fusions, Pioneering Bi-Specific Formats, Potent Antibody Agonists, Self Assembling Monomeric Building Blocks, Standard Manufacturing
Founded	2016
Employees	1-10

Quadrucept Bio Email Formats

Quadrucept Bio uses 1 email format. The most common is {first initial}.{last name} (e.g., j.doe@quadruceptbio.com), used 100% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@quadruceptbio.com	100%

About Quadrucept Bio

Founded by Kymab's former leadership team (acquired by Sanofi in 2021) Quadrucept's QUAD Technology Empowers the Next-Generation of Antibody-based Drugs:- - Super Antagonists: From new or existing Fab or VHH domains - Superior “Receptor Bodies”: High avidity receptor-Fc fusion decoy molecules - Potent Antibody Agonists: Multivalent Fab/VHH receptor clustering - Improved Target Selectivity: Tetravalent low-affinity high-avidity binding - Pioneering Bi-Specifics: Flexible formats tailored for every need - Fc-Multi-valency: Enabling “best-in-class” half-life extension - “One-Two Punch” ADCs: Avidity-driven targeting-Greater payload capacity - Simplicity: Highly efficient self-assembly of monomeric building blocks - Standard Manufacturing: High expression, stability, drug-like properties - Broad and Early Patent Estate: First to the field – All therapeutic targets

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Founder/Owner

Employees by Department

Quadrucept Bio has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

Quadrucept Bio has never raised funding before.

Quadrucept Bio Tech Stack

Discover the technologies and tools that power Quadrucept Bio's digital infrastructure, from frameworks to analytics platforms.

Cloudflare

CDN

Modernizr

JavaScript libraries

Google Workspace

Apache HTTP Server

Web servers

jQuery

JavaScript libraries

MySQL

Databases

GoDaddy

Hosting

Slick

JavaScript libraries

PHP

Programming languages

WordPress

Blogs

PWA

Miscellaneous

OWL Carousel

JavaScript libraries

Frequently asked questions

Quadrucept Bio is located in XX.

Quadrucept Bio generates an estimated annual revenue of $171,110. This revenue figure reflects the company's market position and business performance in its industry.

Quadrucept Bio has an estimated valuation of $547,552. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Quadrucept Bio was founded in 2016, making it 10 years old. The company has established itself as a significant player in its industry over this time.

Quadrucept Bio has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Quadrucept Bio

Steve Arkinstall

Co-Founder and Chief Scientific Officer

4.8

40,000 users